Skip to content

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Gilead Sciences logo
Gilead SciencesGILD
0.9×-0.4×
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
0.0×
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
0.1×0.0×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
0.1×0.0×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
0.1×0.0×

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Current ratio8.1×+0.7×

Where this comes from

Calculated from Kyverna Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s debt-to-equity?
Kyverna Therapeutics, Inc. (KYTX) reported debt-to-equity of 0× in Q1 2026.
How has Kyverna Therapeutics, Inc.'s debt-to-equity changed year-over-year?
Kyverna Therapeutics, Inc.'s debt-to-equity increased by 51.3% year-over-year, from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.